Macquarie Group
APLS

Macquarie Group’s Apellis Pharmaceuticals APLS Stock Holding History

Macquarie Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-65,156
Closed -$1.47M – 888
2025
Q3 		$1.47M Buy
+65,156
New +$1.52M ﹤0.01% 1253
2025
Q2 		– Sell
-204,803
Closed -$4.48M – 1648
2025
Q1 		$4.48M Buy
204,803
+3,736
+2% +$103K 0.01% 1007
2024
Q4 		$6.42M Buy
201,067
+17,778
+10% +$535K 0.01% 892
2024
Q3 		$5.29M Sell
183,289
-1,642
-0.9% -$60.8K 0.01% 953
2024
Q2 		$7.09M Sell
184,931
-36,723
-17% -$1.66M 0.01% 892
2024
Q1 		$13M Sell
221,654
-361,775
-62% -$23.1M 0.01% 766
2023
Q4 		$34.9M Sell
583,429
-493,119
-46% -$25M 0.04% 540
2023
Q3 		$41M Buy
1,076,548
+301,068
+39% +$13.2M 0.05% 461
2023
Q2 		$70.6M Sell
775,480
-635,999
-45% -$54.9M 0.08% 328
2023
Q1 		$93.1M Sell
1,411,479
-50,163
-3% -$2.89M 0.11% 251
2022
Q4 		$75.6M Buy
1,461,642
+40,107
+3% +$2.13M 0.09% 312
2022
Q3 		$97.2M Buy
1,421,535
+38,028
+3% +$2.25M 0.12% 232
2022
Q2 		$62.6M Buy
1,383,507
+61,949
+5% +$2.82M 0.07% 378
2022
Q1 		$67.1K Buy
1,321,558
+29,775
+2% +$1.31M 0.05% 422
2021
Q4 		$61.1M Buy
1,291,783
+171,693
+15% +$6.76M 0.05% 450
2021
Q3 		$36.9M Buy
1,120,090
+574,416
+105% +$32.3M 0.03% 597
2021
Q2 		$34.5M Buy
545,674
+543,529
+25,339% +$28M 0.03% 646
2021
Q1 		$92K Sell
2,145
-717
-25% -$33.9K ﹤0.01% 1933
2020
Q4 		$164K Hold
2,862
– – ﹤0.01% 1731
2020
Q3 		$86K Hold
2,862
– – ﹤0.01% 1823
2020
Q2 		$93K Buy
+2,862
New +$91.9K ﹤0.01% 1771

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Macquarie Group's APLS Position: Q4 2025 in Review

Macquarie Group sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 65,156 shares — an estimated $1.47M sold.

Macquarie Group first reported a position in APLS in Q2 2020 and held it in 21 quarters. The position peaked at $97.2M in Q3 2022. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

  • Macquarie Group reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 65,156 Apellis Pharmaceuticals shares in Q4 2025, an estimated $1.47M.
  • Macquarie Group first reported a position in Apellis Pharmaceuticals in Q2 2020 and held it in 21 quarters.
  • Macquarie Group's Apellis Pharmaceuticals position peaked at $97.2M in Q3 2022.
  • 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.